Colorectal Cancer – Global Drug Forecast and Market Analysis to 2028

Pages: 153 Published: April 30, 2020 Report Code: GDHC182PIDR

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • Listen
    Text to Speech

 

Colorectal cancer (CRC) occurs in the large intestine or large bowel. It is the third most common cancer globally and is one of the most common causes of cancer deaths in the world. Early stage CRC is commonly treated with surgery, while metastatic colorectal cancer (mCRC) treatment is dominated by fluorouracil chemotherapy regimens in combination with angiogenesis inhibitors, primarily Roche’s Avastin, and epidermal growth factor receptor (EGFR) inhibitors.

GlobalData valued the CRC market at $7.6B in 2018. This market is defined as sales of generic chemotherapy and major branded drugs commonly prescribed for CRC patients across the 8MM. GlobalData expects the market to increase to $10.7B in 2028 at a Compound Annual Growth Rate (CAGR) of 3.5%. This global growth is driven by the anticipated approval and launch of 9 pipeline therapies and label expansion of other agents, but will likely be tempered by marked generic erosion of the majority of the currently marketed branded therapies available in 2018.

KEY QUESTIONS ANSWERED

  • Nine late-stage pipeline agents are going to enter the mCRC market from 2018 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in mCRC and which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2018-2028? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Scope

Overview of metastatic colorectal cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline metastatic colorectal cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting metastatic colorectal cancer therapeutics sales in the 8MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global metastatic colorectal cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The main drivers of growth include the anticipated approval and launch of 9 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.

The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.

The rapidly growing aging population will lead to an increase in the CRC incident case in the markets covered in this report. Overall, the diagnosed incident cases of CRC across the 8MM are expected to increase by an Annual Growth Rate (AGR) of 1.9% from 2018–2028.

GlobalData found that there is a large unmet need for the identification of new targets and biomarkers to guarantee the optimal integration of current and future therapies into the treatment paradigm and to improve patient outcomes.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global metastatic colorectal cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global metastatic colorectal cancer cancer market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global metastatic colorectal cancer therapeutics market from 2018-2028.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Key Players

Roche

Amgen

Eli Lilly

Bayer

Bristol-Myers Squibb

Merck KGaA

Merck & Co

Novartis

Pfizer

Sanofi

Taiho

Boston Biomedical

Isofol

Ono Pharmaceuticals

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Colorectal Cancer: Executive Summary

2.1 CRC Market is Expected to Grow to $10.7B in 2028

2.2 Avastin to Remain Leader despiteCompetition from Novel Mechanisms of Action

2.3 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response

2.4 CRC Pipeline Moving Towards Precision Medicine in Both the Early and Metastatic Setting

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems for CRC

4.3 Clinical Presentation

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Sources Not Used

5.4.3 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for CRC

5.5.1 Diagnosed Incident Cases of CRC

5.5.2 Age-Specific Diagnosed Incident Cases of CRC

5.5.3 Sex-Specific Diagnosed Incident Cases of CRC

5.5.4 Diagnosed Incident Cases of CRC by Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of CRC by Molecular Markers

5.5.6 Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis

5.5.7 Diagnosed Incident Cases of CRC by Sidedness

5.5.8 Five-Year Diagnosed Prevalent Cases of CRC

5.5.9 All-Time Diagnosed Prevalent Cases of CRC

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Screening and Diagnosis

6.1.1 Summary

6.1.2 Fecal Testing

6.1.3 Colonoscopy

6.1.4 Flexible Sigmoidoscopy

6.1.5 Computed Tomography Colonography

6.1.6 Recent and Emerging Advances

6.2 Treatment Guidelines

6.3 Clinical Practice

6.4 US

6.4.1 Screening

6.4.2 Treatment Pathways

6.4.3 Biomarker Testing

6.5 5EU

6.5.1 Screening

6.5.2 Treatment Pathways

6.5.3 Biomarker Testing

6.6 Japan

6.6.1 Screening

6.6.2 Treatment Pathways

6.6.3 Biomarker Testing

6.7 China (Urban)

6.7.1 Screening

6.7.2 Treatment Pathways

6.7.3 Biomarker Testing

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Improved Treatments for Patients with KRAS/NRAS Mutations

8.3 Continued Improvement in Precision Medicine

8.4 Reducing Age for Routine Screening

8.5 Overcoming Resistance to Angiogenesis and EGFR-Targeting Therapy

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Roche

10.4 Amgen

10.5 Eli Lilly

10.6 Bayer

10.7 Bristol-Myers Squibb

10.8 Merck KGaA

10.9 Merck & Co.

10.10 Novartis

10.11 Pfizer

10.12 Sanofi

10.13 Taiho

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Drugs Included in Each Therapeutic Class

12.3.4 Launch and Patent Expiry Dates

12.3.5 General Pricing Assumptions

12.3.6 Individual Drug Assumptions for Marketed Products

12.3.7 Individual Drug Assumptions for Off-Label Products

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – Key Opinion Leaders Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Epidemiology Reviewers

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of Tables

Table 1: Colorectal Cancer: Key Metrics in the 8MM

Table 2: 8MM,TNM Staging and Classification for CRC

Table 3: Risk Factors and Comorbid Conditions Associated with CRC

Table 4: 8MM, Diagnosed Incident Cases of CRC by Molecular Markers, N, Both Sexes, Ages ≥18 Years, 2018

Table 5: CRC Disease Management Across the 8MM

Table 6: Treatment Guidelines for CRC

Table 7: Leading Treatments for mCRC, 2018

Table 8: Roche’s CRC Portfolio Assessment, 2020

Table 9: Amgen’s CRC Portfolio Assessment, 2020

Table 10: Eli Lilly’s CRC Portfolio Assessment, 2020

Table 11: Bayer’s CRC Disease Portfolio Assessment, 2020

Table 12: Bristol-Myers Squibb‘s CRC Portfolio Assessment, 2020

Table 13: Merck KGA’s CRC Disease Portfolio Assessment, 2020

Table 14: Merck & Co.’s CRC Disease Portfolio Assessment, 2020

Table 15: Novartis’s CRC Disease Portfolio Assessment, 2020

Table 16: Pfizer’s CRC Portfolio Assessment, 2020

Table 17: Sanofi’s CRC Portfolio Assessment, 2020

Table 18: Taiho’s CRC Disease Portfolio Assessment, 2020

Table 19: CRC Market – Global Drivers and Barriers, 2018–2028

Table 20: Key Events Impacting Sales for CRC in the US, 2018–2028

Table 21: CRC Drivers and Barriers in the US, 2018–2028

Table 22: Key Events Impacting Sales for CRC in the 5EU, 2018–2028

Table 23: CRC – Drivers and Barriers in the 5EU, 2018–2028

Table 24: Key Events Impacting Sales for CRC in Japan, 2018–2028

Table 25: CRC – Global Drivers and Barriers in Japan, 2018–2028

Table 26: Key Events Impacting Sales for CRC in China, 2018–2028

Table 27: CRC – Global Drivers and Barriers in China, 2018–2028

Table 28: Key Historical and Projected Launch Dates for CRC

Table 29: Key Historical and Projected Patent Expiry Dates for mCRC

Table 30: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for CRC in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in CRC During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage CRC Pipeline Agents

Figure 4: Diagram of the Cancers of the Colon and Rectum

Figure 5: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Men, Ages ≥18 Years, 2018–2028

Figure 6: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Women, Ages ≥18 Years, 2018–2028

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC

Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed and Diagnosed Prevalent Cases of CRC

Figure 9: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CRC by Stage at Diagnosis

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers

Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastases

Figure 12: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Sidedness

Figure 13: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, ≥18 Years, 2018

Figure 14: 8MM, Age-Specific Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018

Figure 15: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, N, Ages ≥18 Years, 2018

Figure 16: 8MM, Diagnosed Incident Cases of CRC by Stage at Diagnosis, N, Both Sexes, Ages ≥18 Years, 2018

Figure 17: 8MM, Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis, N, Both Sexes, Ages ≥18 Years, 2018

Figure 18: 8MM, Diagnosed Incident Cases of CRC by Sidedness, N, Both Sexes, Ages ≥18 Years, 2018

Figure 19: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018

Figure 20: 8MM, Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018

Figure 21: Unmet Needs and Opportunities in CRC

Figure 22: Overview of the Development Pipeline in CRC

Figure 23: Key Phase II/III Trials for Promising CRC Pipeline Agents

Figure 24: Competitive Assessment of the Late-Stage CRC Pipeline Agents

Figure 25: Analysis of the Company Portfolio Gap in mCRC During the Forecast Period

Figure 26: 8MM, Sales Forecast by Country for CRC in 2018 and 2028

Figure 27: 8MM, Sales Forecast by Drug Class for CRC in 2018 and 2028

Figure 28: Sales Forecast by Class for CRC in the US, 2018 and 2028

Figure 29: Sales Forecast by Class for CRC in the EU, 2018 and 2028

Figure 30: Sales Forecast by Class for CRC in Japan in 2018 and 2028

Figure 31: Sales Forecast by Class for CRC in China in 2018 and 2028

$10995

Can be used by individual purchaser only

$32985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.